Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer.
Soria, J-C Márk, Z Zatloukal, P Szima, B Albert, I Juhász, E Pujol, J L Kozielski, J Baker, N Smethurst, D
Soria, J-C
Márk, Z
Zatloukal, P
Szima, B
Albert, I
Juhász, E
Pujol, J L
Kozielski, J
Baker, N
Smethurst, D
Citations
Altmetric:
Abstract
To evaluate the efficacy and safety of dulanermin combined with paclitaxel and carboplatin (PC) and bevacizumab (PCB) as first-line treatment for advanced or recurrent non-small-cell lung cancer (NSCLC).
Description
Date
2011-11-20
Publisher
Collections
Keywords
Type
Article
Citation
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. 2011, 29 (33):4442-51 J Clin Oncol